Palisade Bio Beheer

Beheer criteriumcontroles 1/4

De CEO Palisade Bio is J. Finley, benoemd in Apr2021, heeft een ambtstermijn van 3.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.28M, bestaande uit 40.7% salaris en 59.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.01% van de aandelen van het bedrijf, ter waarde $ 32.87K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 0.8 jaar.

Belangrijke informatie

J. Finley

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	40.7%
Dienstverband CEO	3.6yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Jul 27

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Jun 29

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Mar 28

Palisade Bio: Guarding Intestinal Integrity

Nov 07

Analyse CEO-vergoeding

Hoe is J. Finley's beloning veranderd ten opzichte van Palisade Bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$1m	US$520k	-US$12m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$614k	US$441k	-US$15m
Sep 30 2022	n/a	n/a	-US$9m
Jun 30 2022	n/a	n/a	-US$358k
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	US$1m	US$365k	-US$27m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$532k	US$293k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.28M ) J. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van J. is gestegen terwijl het bedrijf verliesgevend is.

CEO

J. Finley (67 yo)

3.6yrs

Tenure

US$1,277,100

Compensatie

Mr. J. D. Finley serves as its Chief Executive Officer of Palisade Bio, Inc. since 2023 and has been its Director since February 2023. He serves as the Chief Financial Officer at Palisade Bio, Inc. (Altern...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
J. Finley	CEO, CFO & Director	3.6yrs	US$1.28m	1.01% $ 32.9k
Mitchell Jones	COO & Chief Medical Officer	1.2yrs	US$738.81k	0.29% $ 9.4k
Joerg Heyer	Head of Translational Science & Medicine	less than a year	geen gegevens	geen gegevens
Ryker Willie	Senior VP of Finance & Corporate Controller	6.4yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van PALI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
J. Finley	CEO, CFO & Director	1.8yrs	US$1.28m	1.01% $ 32.9k
Margery Fischbein	Independent Director	less than a year	geen gegevens	0% $ 0
Donald Williams	Independent Chairman of the Board	3.6yrs	US$87.23k	0.25% $ 8.1k
Bruce Sands	Member of Clinical Advisory Board	less than a year	geen gegevens	geen gegevens
Florian Rieder	Member of Clinical Advisory Board	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PALI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

Palisade Bio Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. Announces Advisory Board Appointments

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Recent updates

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Price target increased by 33% to US$45.00

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

New major risk - Financial position

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Price target decreased by 33% to US$22.50

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Price target decreased by 81% to US$3.00

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

New major risk - Market cap size

Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million.

Palisade Bio, Inc. announced that it has received funding

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Price target decreased to US$3.00

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Palisade Bio, Inc. Announces Executive Changes

Palisade Bio, Inc. Announces Chief Executive Officer Transition

Palisade Bio announces CEO transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022

Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148

Palisade Bio streamlines operations, including cutting 20% of employees

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio GAAP EPS of -$0.12

Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million.

Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio, Inc. announced a financing transaction

Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148

Price target decreased to US$4.00

High number of new directors

Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development

Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

High number of new and inexperienced directors

Palisade Bio: Guarding Intestinal Integrity

Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center

Palisade Bio, Inc. announced delayed 10-Q filing

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China